Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherBrowse by ChannelAbout the NetworkJoin the NetworkProductsSub-MenuProducts OverviewBlog ProBlog PlusBlog PremierMicrositeSyndication PortalsAbout UsContactSubscribeSupport
Book a Demo
Search
Close

FDA Accepts BLA for Amneal’s Denosumab Biosimilars

March 12, 2025

FDA Accepts BLA for Shanghai Henlius Biotech’s HLX11, a Pertuzumab Biosimilar

February 6, 2025

Teva and mAbxience Add Additional Oncology Biosimilar Candidate, Expanding Strategic Partnership

October 16, 2024

Update on Recent International Biosimilar Approvals

September 26, 2023

GSK Sues Pfizer for Patent Infringement over RSV Vaccine

August 21, 2023

Fresenius Kabi Launches STIMUFEND (pegfilgrastim-fpgk) in the United States

February 24, 2023

Fresenius Kabi Announces FDA Approval of Adalimumab Biosimilar

December 14, 2022

Biogen Announces EMA Acceptance of Tocilizumab Biosimilar Application

October 11, 2022

Teva Receives Approval for First Ophthalmology Biosimilar in Europe

May 19, 2022

Biogen Sells Bioepis Stake for $2.3 Billion to Samsung Biologics

February 4, 2022
Subscribe: Subscribe via RSS
Blogs
  • Big Molecule Watch
Firm/Org
  • Goodwin Procter

Jenevieve Nutovits

Subscribe: Subscribe via RSS
Blogs
  • Big Molecule Watch
Firm/Org
  • Goodwin Procter
LexBlog, Inc. logo
Facebook LinkedIn Twitter RSS
Real Lawyers
99 Park Row
  • About LexBlog
  • Careers
  • Press
  • Contact LexBlog
  • Privacy Policy
  • Editorial Policy
  • Disclaimer
  • Terms of Service
  • RSS Terms of Service
  • Products
  • Blog Pro
  • Blog Plus
  • Blog Premier
  • Microsite
  • Syndication Portals
  • LexBlog Community
  • Resource Center
  • 1-800-913-0988
  • Submit a Request
  • Support Center
  • System Status
  • Resource Center
  • Blogging 101

New to the Network

  • Tennessee Insurance Litigation Blog
  • Claims & Sustains
  • New Jersey Restraining Order Lawyers
  • New Jersey Gun Lawyers
  • Blog of Reason
Copyright © 2025, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo